Physician profile
John R Wilson
NPI 1548243678
$28,135.25
in general payments reported to CMS, 2019-2025
69 companies · $4,846 in 2025
The $4,846 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,756 · 2020: $3,223 · 2021: $4,568 · 2022: $3,786 · 2023: $4,036 · 2024: $4,920 · 2025: $4,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $25.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,777.10 |
| Education | $25.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,585.82 | 2019-2025 | Ubrelvy, Qulipta, Duopa |
| Biogen, INC. | $2,516.47 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $2,279.08 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $2,030.15 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $1,815.57 | 2019-2025 | |
| Lilly USA, LLC | $1,159.47 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Pfizer INC. | $1,062.78 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $1,024.71 | 2019-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $809.84 | 2019-2025 | Mavenclad |
| Sk Life Science, INC. | $792.88 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $708.12 | 2019-2022 | |
| Lundbeck LLC | $626.28 | 2019-2025 | Rexulti, Vyepti |
| Celgene Corporation | $594.02 | 2021-2025 | Zeposia |
| Genentech USA, INC. | $526.06 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $491.06 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $473.92 | 2019-2025 | Gocovri, Gocovri, Xadago |
| Kyowa Kirin, INC. | $412.40 | 2020-2024 | Nourianz |
| Neurocrine Biosciences, INC. | $379.45 | 2020-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $369.06 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $368.34 | 2021 | |
| Vanda Pharmaceuticals INC. | $365.10 | 2024-2025 | Ponvory |
| Avanir Pharmaceuticals, INC. | $357.56 | 2019-2022 | |
| Amgen INC. | $355.39 | 2019-2023 | Aimovig |
| Janssen Pharmaceuticals, INC | $354.70 | 2021-2022 | |
| Livanova USA, INC. | $353.24 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Cycle Pharmaceuticals INC | $351.43 | 2024-2025 | Tascenso Odt, Bafiertam |
| Eisai INC. | $343.93 | 2019-2025 | |
| Csl Behring | $343.17 | 2020-2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $326.34 | 2023-2025 | Nuedexta, Rexulti |
| Sumitomo Pharma America, INC. | $291.91 | 2023-2024 | Aptiom |
| Sanofi-Aventis U.S. LLC | $284.44 | 2020-2021 | |
| Acorda Therapeutics, INC | $269.06 | 2019-2024 | Ampyra, Inbrija |
| Allergan, INC. | $253.23 | 2019-2020 | |
| Hospira, INC. | $242.12 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $217.59 | 2019-2025 | Nuplazid |
| Grifols USA, LLC | $191.05 | 2023-2025 | Gamunex-C |
| Jazz Pharmaceuticals INC. | $136.65 | 2019-2025 | |
| Banner Life Sciences, LLC | $135.40 | 2022-2024 | |
| Abbott Laboratories | $130.04 | 2019-2023 | Infinity |
| Akcea Therapeutics, INC. | $129.65 | 2019-2021 | |
| Axsome Therapeutics, INC. | $123.46 | 2025 | Symbravo |
| Catalyst Pharmaceuticals, INC. | $121.21 | 2020-2025 | Fycompa |
| Longeviti Neuro Solutions INC | $116.47 | 2023 | |
| Arbor Pharmaceuticals, INC. | $114.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $104.69 | 2023-2025 | Wainua, Evusheld |
| Upsher-Smith Laboratories LLC | $101.71 | 2019-2020 | |
| Octapharma USA, INC. | $94.25 | 2024-2025 | Panzyga |
| Supernus Pharmaceuticals, INC. | $92.85 | 2019-2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $79.08 | 2019-2020 | |
| Inspire Medical Systems, INC. | $72.90 | 2023-2025 | Inspire |
| Zyla Life Sciences, INC. | $71.09 | 2019 | |
| Tanabe Pharma America, INC. | $69.10 | 2022-2025 | Radicava |
| Avion Pharmaceuticals | $60.21 | 2022 | |
| Bausch Health US, LLC | $59.65 | 2019 | |
| Amneal Pharmaceuticals LLC | $50.77 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.93 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.82 | 2022 | |
| Adamas Pharmaceuticals, INC. | $35.11 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $33.51 | 2025 | |
| Merz Pharmaceuticals, LLC | $28.48 | 2024 | Xeomin |
| Springworks Therapeutics, INC. | $24.49 | 2025 | Gomekli |
| Corium, LLC | $24.02 | 2023 | Adlarity |
| Kedrion Biopharma, INC. | $23.75 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Impel Pharmaceuticals INC. | $20.80 | 2023 | Trudhesa |
| Aprecia Pharmaceuticals, LLC | $20.56 | 2023 | Spritam |
| Bio Products Laboratory USA, INC. | $20.56 | 2023 | Coagadex, Gammaplex |
| Portola Pharmaceuticals, LLC | $15.52 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.78 | 2024 | Keveyis |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.